Effect of respiratory syncytial virus on the activity of matrix metalloproteinase in mice

Chinese Medical Journal

Volumn 120, Issue 1, 2007, Pages 5-11

  Li, Wen ^a   Shen, Hua Hao ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

E caherin; Inhibitory agents; Matrix metalloproteinase; Proliferating cell nuclear antigen; Respiratory syncytial virus

Indexed keywords

CYCLINE; GELATIN; GELATINASE A; GELATINASE B; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOWER RESPIRATORY TRACT INFECTION; LUNG FIBROSIS; LUNG LAVAGE; LUNG PARENCHYMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; STATISTICAL SIGNIFICANCE; UPREGULATION; VIRUS PATHOGENESIS; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 33846286153     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200701010-00002     Document Type: Article

References (22)

1. The Respiratory Disease Branch of Chinese Medical Association. Guide for the diagnosis and management of chronic obstructive pulmonary disease. Chin J Tuberc Respir Dis (Chin) 2002; 25: 453-460.
2. Daheshia M. Therapeutic inhibition of matrix metalloproteinases for the treatment of chronic obstructive pulmonary disease (COPD). Curr Med Res Opin 2005; 21: 587-594.
3. Suzuki R, Miyazaki Y, Takagi K, Torii K, Taniguchi H. Matrix metalloproteinases in the pathogenesis of asthma and COPD: implications for therapy. Treat Respir Med 2004; 3: 17-27.
4. Elkington PT, Friedland JS. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006; 61: 259-266.
5. Chakrabarti S, Patel KD. Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp Lung Res 2005; 31: 599-621.
6. Falsey AR, Formica MA, Hennessey PA, Criddle MM, Sullender WM, Walsh EE. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 639-643.
7. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352: 1749-1759.
8. Rohde G, Wiethege A, Borg I, Kauth M, Bauer TT, Gillissen A, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003; 58: 37-42.
9. Gualano RC, Vlahos R, Anderson GP. What is the contribution of respiratory viruses and lung proteases to airway remodelling in asthma and chronic obstructive pulmonary disease? Pulm Pharmacol Ther 2006; 19: 18-23.
10. Domachowske JB, Bonville CA, Rosenberg HF. Animal models for studying respiratory syncytial virus infection and its long term effects on lung function. Pediatr Infect Dis J 2004; 23(11 Suppl): S228-234.
11. Colasurdo GN, Fullmer JJ, Elidemir O, Atkins C, Khan AM, Stark JM. Respiratory syncytial virus infection in a murine model of cystic fibrosis. J Med Virol 2006; 78: 651-658.
12. Mejias A, Chavez-Bueno S, Rios AM, Aten MF, Raynor B, Peromingo E, et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother 2005; 49: 4700-4707.
13. Lian GL, Yu HG, Zhao XD, Zhao XQ. Establishment of respiratory syncytial virus infection model in mice. J Xi'an Jiaotong Univ (Med Sci) (Chin) 2003; 23: 329-332.
14. Bremnes RM, Veve R, Hirsch FR, Franklin WA. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer 2002; 36: 115-124.
15. Charalabopoulos K, Gogali A, Kostoula OK, Constantopoulos SH. Cadherin superfamily of adhesion molecules in primary lung cancer. Exp Oncol 2004; 26: 256-260.
16. Nozawa N, Hashimoto S, Nakashima Y, Matsuo Y. Koga T, Sugio K, et al. Immunohistochemical alpha- and beta-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma. Pathol Res Pract 2006; 202: 639-650.
17. Douglas IS, Diaz del Valle F, Winn RA, Voelkel NF. Beta-catenin in the fibroproliferative response to acute lung injury. Am J Respir Cell Mol Biol 2006; 34: 274-285.
18. Wang WM, Li JC, Zhang HJ, Yang Y, Yang GY. Effect of Huchang Qingfei concentrated pellets on E-cadherin expression in lung tissue of mice infected with Mycoplasma pneumoniae. China J Chin Materia Medica (Chin) 2005; 30: 1682-1685.
19. Muramatsu M, Takai S, Miyazaki M. Detections of matrix metalloproteinases activities and localization by film in situ zymography (FIZ). Nippon Yakurigaku. Zasshi 2003; 121: 113-118.
20. Cataldo DD, Gueders MM, Rocks N, Sounni NE, Evrard B, Bartsch P, et al. Pathogenic role of matrix metalloproteases and their inhibitors in asthma and chronic obstructive pulmonary disease and therapeutic relevance of matrix metalloproteases inhibitors. Cell Mol Biol (Noisy-le-grand) 2003; 49: 875-884.
21. Finlay GA, O'Driscoll LR, Russell KJ, D'Arcy EM, Masterson JB, FitzGerald MX, et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997; 156: 240-247.
22. Li W, Xu YJ, Zhang ZX. Activity of matrix metalloproteinase in airway epithelial cells of COPD patients. J Huazhong Univ Sci Technology Med Sci 2005; 25: 151-154.